Chemistry:MRTX1133

From HandWiki

MRTX1133 is an investigational drug that targets the G12D mutation in KRAS dependent cancers.[1][2] MRTX1133 was in a phase 1/2 clinical trial for the treatment of solid tumors,[3] however the study was terminated in Q1 2025.[4] MRTX1133 is considered to be harmful from direct skin or eye exposure other than transient irritation. It may cause irritation of the respiratory system if inhaled.[5]

See also

References

  1. ↑ "MRTX 1133". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800059927. 
  2. ↑ "Next batter up! Targeting cancers with KRAS-G12D mutations". Trends in Cancer 9 (11): 955–967. November 2023. doi:10.1016/j.trecan.2023.07.010. PMID 37591766. 
  3. ↑ Clinical trial number NCT05737706 for "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation" at ClinicalTrials.gov
  4. ↑ "Bristol exits KRAS G12D". ApexOnco. https://www.oncologypipeline.com/apexonco/bristol-exits-kras-g12d. 
  5. ↑ "MRTX1133 Safety Data Sheet". TargetMol. https://archive.org/details/mrtx-1133-sds. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:MRTX1133&oldid=4036902"